Oculis Holding AG

NasdaqGM:OCS Stock Report

Market Cap: US$698.1m

Oculis Holding Future Growth

Future criteria checks 2/6

Oculis Holding is forecast to grow earnings and revenue by 13.1% and 61.1% per annum respectively. EPS is expected to grow by 22.6% per annum. Return on equity is forecast to be -57.8% in 3 years.

Key information

13.1%

Earnings growth rate

22.63%

EPS growth rate

Pharmaceuticals earnings growth14.8%
Revenue growth rate61.1%
Future return on equity-57.77%
Analyst coverage

Good

Last updated10 Jun 2026

Recent future growth updates

Recent updates

Seeking Alpha • Jun 02

Oculis Holding: Study Setback For Eye Drop Therapy Suggests Hold Rating

Summary Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary and key secondary endpoints. OCS-01 will not move forward for FDA filing in DME, undermining the company's main value driver and casting doubt on its near-term commercial prospects. Attention shifts to pipeline assets Licaminlimab (dry eye disease, Phase 3) and Privosegtor (optic neuropathies), but competitive and data risks remain significant. With $277.6m cash and a >$800m market cap, I remain on the sidelines, unconvinced of a 'Buy the Dip' opportunity until further clinical catalysts materialize. Read the full article on Seeking Alpha
Seeking Alpha • Jan 21

Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care

Summary Oculis' main value driver appears to be OCS-01, which targets a respectable $4 billion DME TAM with its non-invasive eye drops. Eye injections are tough on patients, so this bodes well for OCS-01. OCS-05 and OCS-02 also target interesting TAMs in neuro-ophthalmology and DMD. OCS’s cash runway should last until late 2026, but if they don’t generate an FDA-approved product soon, it could become an issue for shareholders. Still, I see a few catalysts with upcoming regulatory milestones, like an NDA for OCS-01 in Q1, that could help sustain OCS stock’s valuation. I recommend a DCA strategy because Oculis stock might consolidate after such an impressive rally recently. Read the full article on Seeking Alpha
Seeking Alpha • Nov 04

Oculis: Lack Of Coverage Only Real Risk For This Solid Company

Summary Oculis has multiple late-stage programs and catalysts. Trading volume is low, and there's hardly any coverage in the US. Barring the low liquidity, OCS looks attractive. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGM:OCS - Analysts future estimates and past financials data (CHF Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202842-112-30-847
12/31/20278-112-34-8310
12/31/20261-103-49-9610
3/31/20261-95-63-63N/A
12/31/20251-99-68-66N/A
9/30/20251-104-60-59N/A
6/30/20251-107-58-56N/A
3/31/20251-103-55-54N/A
12/31/20241-86-49-49N/A
9/30/20241-70-51-51N/A
6/30/20241-67-52-52N/A
3/31/20241-59-52-52N/A
12/31/20231-89-55-55N/A
9/30/20231-85-49-47N/A
6/30/20231-78-44-42N/A
3/31/20231-75-38-35N/A
12/31/20221-39-29-25N/A
9/30/20221-35-24-22N/A
6/30/20221-30-21-20N/A
3/31/20221-24-18-17N/A
12/31/20211-19-14-14N/A
12/31/20201-15-12-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OCS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OCS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OCS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OCS's revenue (61.1% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: OCS's revenue (61.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: OCS is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/25 02:04
End of Day Share Price 2026/06/25 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oculis Holding AG is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Jason Matthew GerberryBofA Global Research
Daniil GataulinChardan Capital Markets, LLC